Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neogenomics Inc NEO

Healthcare
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical... see more

Recent & Breaking News (NDAQ:NEO)

NeoGenomics to Announce First Quarter 2023 Financial Results

Accesswire April 17, 2023

NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Accesswire April 11, 2023

NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023

Accesswire April 6, 2023

NeoGenomics to Host Investor Day on April 4, 2023

Accesswire March 27, 2023

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

Business Wire March 22, 2023

NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test

Accesswire March 16, 2023

NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP

Accesswire March 13, 2023

NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference

Accesswire February 28, 2023

NeoGenomics Reports Fourth Quarter and Full Year 2022 Results

Accesswire February 23, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of NeoGenomics Laboratories, Inc. (NEO) Investigation

Business Wire February 8, 2023

NEO IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages NeoGenomics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action - NEO

PR Newswire February 7, 2023

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NeoGenomics, Inc. (NEO) Investors of Class Action and to Actively Participate

Business Wire February 6, 2023

NeoGenomics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your Rights - NEO

Newsfile February 6, 2023

RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery

Accesswire February 6, 2023

NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023

Accesswire February 6, 2023

NEOGENOMICS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In NeoGenomics To Contact Him Directly To Discuss Their Options

PR Newswire February 4, 2023

NEOGENOMICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against NeoGenomics, Inc. - NEO

Business Wire February 3, 2023

NEOGENOMICS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against NeoGenomics, Inc. and Encourages Investors to Contact the Firm

Business Wire February 3, 2023

NeoGenomics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your Rights - NEO

Newsfile February 3, 2023

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NEO)

Business Wire February 3, 2023